Piper Jaffray Companies initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report sent to investors on Friday, November 16th, Marketbeat reports. The brokerage issued an overweight rating and a $15.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on BCRX. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, August 8th. BidaskClub cut shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, July 28th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, November 7th. Royal Bank of Canada reiterated a buy rating and set a $9.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group reiterated a buy rating and set a $8.50 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $11.41.

BCRX stock traded down $0.17 during trading on Friday, reaching $8.78. 632,122 shares of the stock were exchanged, compared to its average volume of 735,851. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.00 and a quick ratio of 1.98. BioCryst Pharmaceuticals has a 1 year low of $4.25 and a 1 year high of $9.70. The company has a market capitalization of $981.29 million, a PE ratio of -11.26 and a beta of 1.78.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. The firm had revenue of $1.45 million for the quarter, compared to analysts’ expectations of $2.53 million. Sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.99 EPS for the current year.

In other news, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction that occurred on Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total transaction of $71,314.00. Following the completion of the sale, the insider now owns 140,633 shares in the company, valued at approximately $1,018,182.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas R. Staab II sold 3,922 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $9.45, for a total transaction of $37,062.90. The disclosure for this sale can be found here. Insiders have sold a total of 135,562 shares of company stock valued at $1,164,765 in the last quarter. 4.50% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. Baker BROS. Advisors LP lifted its position in shares of BioCryst Pharmaceuticals by 7.8% during the 3rd quarter. Baker BROS. Advisors LP now owns 15,103,081 shares of the biotechnology company’s stock worth $115,237,000 after buying an additional 1,090,909 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of BioCryst Pharmaceuticals by 10.4% during the 3rd quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock worth $93,469,000 after buying an additional 1,153,978 shares during the last quarter. BlackRock Inc. lifted its position in shares of BioCryst Pharmaceuticals by 13.1% during the 3rd quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after buying an additional 1,013,905 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of BioCryst Pharmaceuticals by 9.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after buying an additional 490,319 shares during the last quarter. Finally, Jennison Associates LLC lifted its position in shares of BioCryst Pharmaceuticals by 10.9% during the 3rd quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock worth $29,376,000 after buying an additional 378,565 shares during the last quarter. Institutional investors and hedge funds own 91.34% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

See Also: Preferred Stock

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.